Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stig Lenhoff

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Blood|September 10, 2015
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantationChristoph Schmid, Myriam Labopin, Gerard Socié, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q DeletionLaurent Garderet, Dimitris Ziagkos, Anja van Biezen, et al.
Haematologica|February 9, 2018
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMTNico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, et al.
Hemasphere|February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working PartyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Blood|April 26, 2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialUlf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, et al.
Bone Marrow Transplantation|January 23, 2022
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
Bone Marrow Transplantation|November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMatjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Bone Marrow Transplantation|April 1, 2022
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Haematologica|December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemiaEolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Blood|September 10, 2015
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantationChristoph Schmid, Myriam Labopin, Gerard Socié, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q DeletionLaurent Garderet, Dimitris Ziagkos, Anja van Biezen, et al.
Haematologica|February 9, 2018
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMTNico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, et al.
Hemasphere|February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working PartyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Blood|April 26, 2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialUlf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, et al.
Bone Marrow Transplantation|January 23, 2022
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
Bone Marrow Transplantation|November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMatjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Bone Marrow Transplantation|April 1, 2022
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
Pageof 8